(Q51804590)

12 April 2018

title

Animal models and antibody assays for evaluating candidate SARS vaccines: summary of a technical meeting 25-26 August 2005, London, UK. (English)

1 reference

12 April 2018

0 references

3

1 reference

12 April 2018

Anjeanette Roberts

1

object named as

Anjeanette Roberts

1 reference

12 April 2018

author name string

John Wood

2

1 reference

12 April 2018

Morag Ferguson

4

1 reference

12 April 2018

David Wood

5

1 reference

12 April 2018

Thomas Cherian

6

1 reference

12 April 2018

language of work or name

English

0 references

publication date

18 July 2006

1 reference

12 April 2018

number of pages

10

1 reference

inferred from page(s)

published in

Vaccine

1 reference

12 April 2018

volume

24

1 reference

12 April 2018

page(s)

7056-7065

1 reference

12 April 2018

issue

49-50

1 reference

12 April 2018

Severe acute respiratory syndrome

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

WHO investigates China's fall in SARS cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

WHO says SARS outbreak is over, but fight should go on.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Coronavirus as a possible cause of severe acute respiratory syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

The Genome sequence of the SARS-associated coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

SARS coronavirus: a new challenge for prevention and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

The aetiology, origins, and diagnosis of severe acute respiratory syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Structural biology. Adaptation of SARS coronavirus to humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Bats are natural reservoirs of SARS-like coronaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Virology: SARS virus infection of cats and ferrets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Aetiology: Koch's postulates fulfilled for SARS virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Effects of a SARS-associated coronavirus vaccine in monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Macaque model for severe acute respiratory syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Identification of the membrane-active regions of the severe acute respiratory syndrome coronavirus spike membrane glycoprotein using a 16/18-mer peptide scan: implications for the viral fusion mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Symptoms of infection caused by SARS coronavirus in laboratory mice and guinea pigs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Civets are equally susceptible to experimental infection by two different severe acute respiratory syndrome coronavirus isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Immunogenicity of SARS inactivated vaccine in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Antibody-Dependent Enhancement of Virus Infection and Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Neutralization and antibody-dependent enhancement of dengue viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

SARS-coronavirus replicates in mononuclear cells of peripheral blood (PBMCs) from SARS patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

SARS-coronavirus replication in human peripheral monocytes/macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Hepatitis A immunoglobulin: an international collaborative study to establish the second international standard

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

The 1st International Standard for anti-measles serum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Calibration of a replacement preparation for the International Standard for Rabies Immunoglobulin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Report of a collaborative study to calibrate the Second International Standard for parvovirus B19 antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Medicine. Caution urged on SARS vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

Localization of antigenic sites of the S glycoprotein of feline infectious peritonitis virus involved in neutralization and antibody-dependent enhancement.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

7 January 2021

inferred from DOI database lookup

Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

7 January 2021

inferred from DOI database lookup

Intracellular transport of recombinant coronavirus spike proteins: implications for virus assembly

2 references

12 December 2020

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.009

7 January 2021

inferred from DOI database lookup

SARS Immunity and Vaccination.

1 reference

12 December 2020

The importance of standardisation of laboratory evaluations in HIV vaccine trials.

1 reference

12 December 2020

Infection of SARS-CoV on juvenile and adult Brandt's voleMicrotus brandtii

1 reference

12 December 2020

Antibody-mediated enhancement of viral disease.

1 reference

12 December 2020

10.1016/J.VACCINE.2006.07.009

Identifiers

DOI

1 reference

12 April 2018

PubMed ID

16930781

1 reference

12 April 2018